TABLE 2.
Clinical and pathological features according to the differential SFTA2 expression in 1,000 NSCLC patients from the TCGA database.
| Low SFTA2 expression | High SFTA2 expression | p-value | ||
|---|---|---|---|---|
| Progression status | Progression | 195 | 161 | 0.030* |
| Progression free | 312 | 346 | ||
| Mean (SD) | 65.6 (9.6) | 66.9 (9.1) | ||
| Sex | Female | 271 | 135 | <0.001 |
| Male | 236 | 372 | ||
| Race | American Indian | 1 | 0.955 | |
| Asian | 8 | 8 | ||
| Black | 44 | 38 | ||
| White | 385 | 351 | ||
| pT stage | T1 | 72 | 44 | <0.001 |
| T1a | 50 | 21 | ||
| T1b | 51 | 44 | ||
| T2 | 160 | 179 | ||
| T2a | 79 | 90 | ||
| T2b | 26 | 35 | ||
| T3 | 47 | 71 | ||
| T4 | 19 | 23 | ||
| TX | 3 | |||
| pN stage | N0 | 323 | 326 | <0.001 |
| N1 | 93 | 133 | ||
| N2 | 72 | 42 | ||
| N3 | 5 | 2 | ||
| NX | 13 | 4 | ||
| pM stage | M0 | 351 | 404 | 0.003 |
| M1 | 16 | 7 | ||
| M1a | 2 | 1 | ||
| M1b | 3 | 3 | ||
| MX | 131 | 88 | ||
| pTNM stage | I | 5 | 3 | <0.001 |
| IA | 136 | 84 | ||
| IB | 127 | 163 | ||
| II | 1 | 3 | ||
| IIA | 53 | 62 | ||
| IIB | 68 | 96 | ||
| IIIA | 72 | 64 | ||
| IIIB | 15 | 14 | ||
| IV | 22 | 11 | ||
| III | 3 | |||
| Metastasis status | Metastasis | 59 | 37 | 0.865 |
| Metastasis: primary | 1 | 2 | ||
| Metastasis: recurrence | 7 | 4 | ||
| Smoking history | Non-smoking | 70 | 22 | <0.001 |
| Smoking | 422 | 474 | ||
| Radioation history | Non-radiation | 143 | 137 | <0.001 |
| Radiation | 12 | 16 |
*p value <0.05 are marked in bold.